You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Hormone sensitive prostate cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Hormone-Sensitive Prostate Cancer Trial (Rezvilutamide, Rezvilutamide plus abiraterone, Continue previous treatment)

Not yet recruiting
  • Metastatic Hormone-Sensitive Prostate Cancer
  • (no location specified)
Nov 10, 2023

Learn More About How Safe Darolutamide is Under Real-world

Not yet recruiting
  • Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
  • No Intervention
  • Multiple Locations, Japan
    Many Locations
Aug 24, 2023

Apalutamide in Metastatic Hormone Sensitive Prostate Cancer

Not yet recruiting
  • Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
    • Cardiff, United Kingdom
    • +4 more
    Aug 25, 2023

    Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer, Chemo Effect Trial in Nanjing (Docetaxel, Rezvilutamide)

    Recruiting
    • Metastatic Prostate Cancer
    • +2 more
    • Nanjing, Jiangsu, China
      Urology dpt, First Affiliated Hospital of Nanjing Medical Univer
    Aug 2, 2023

    High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC) Trial (dalpiciclib isethionate tablets; abiraterone acetate

    Not yet recruiting
    • High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)
    • dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets
    • placebo; abiraterone acetate tablets; prednisone tablets
    • (no location specified)
    Oct 20, 2023

    Prostate Cancer, Radiotherapy Side Effect, Metastatic Cancer Trial in Umeå (Moderate hypo-fractionation,

    Recruiting
    • Prostate Cancer
    • +2 more
    • Moderate hypo-fractionation
    • Ultra-hypo-fractionation
    • Umeå, Sweden
      Cancercenter University hospital of Umeå
    Nov 1, 2022

    Oligometastatic Hormone Sensitive Prostate Cancer Trial in Florence (SBRT on all sites of metastatic disease+Apalutamide)

    Not yet recruiting
    • Oligometastatic Hormone Sensitive Prostate Cancer
    • SBRT on all sites of metastatic disease+Apalutamide
    • Florence, Italy
      AOU Careggi Radiation Oncology Unit
    Jan 29, 2023

    Prostate Cancer Trial in Chicago (Docetaxel, ADT, Abiraterone)

    Not yet recruiting
    • Prostate Cancer
    • Chicago, Illinois
      Northwestern University
    Sep 27, 2023

    Metastatic Hormone-Sensitive Prostate Cancer Trial in Saint Louis (biological, drug, device, procedure)

    Completed
    • Metastatic Hormone-Sensitive Prostate Cancer
    • PROSTVAC-V
    • +9 more
    • Saint Louis, Missouri
      Washington University School of Medicine
    Aug 3, 2022

    Hormone Sensitive Metastatic Prostate Cancer, DNA Damage Repair Deficiency, Chemo Effect Trial in Nanjing (Docetaxel,

    Recruiting
    • Hormone Sensitive Metastatic Prostate Cancer
    • +3 more
    • Nanjing, Jiangsu, China
      Department of Urology, Drum Tower Hospital, Medical School of Na
    Jul 13, 2022

    Metastatic Hormone Refractory Prostate Cancer Trial in Saint Louis (Cabozantinib, Nivolumab, Abiraterone acetate)

    Recruiting
    • Metastatic Hormone Refractory Prostate Cancer
    • Saint Louis, Missouri
      Washington University School of Medicine
    Jun 6, 2022

    Based Discrete Choice Experiment Study in Prostate Cancer Study

    Completed
    • Prostate Cancer
    • Metastatic Hormone-sensitive Prostate Cancer
      • Durham, North Carolina
        Duke Clinical Research Institute
      Jan 10, 2023

      Hormone Sensitive Prostate Cancer Trial in Qingdao (SHR7280)

      Recruiting
      • Hormone Sensitive Prostate Cancer
      • Qingdao, Shandong, China
        The Affiliated Hospital of Qingdao University
      Jan 13, 2022

      Metastatic Hormone-sensitive Prostate Cancer Trial in United States (Darolutamide (BAY1841788, Nubeqa), ADT)

      Recruiting
      • Metastatic Hormone-sensitive Prostate Cancer
      • Darolutamide (BAY1841788, Nubeqa)
      • ADT
      • Homewood, Alabama
      • +11 more
      Jan 13, 2023

      Prostate Cancer Trial in Utrecht (PSMA-PET/CT response evaluation)

      Not yet recruiting
      • Prostate Cancer
      • PSMA-PET/CT response evaluation
      • Utrecht, Netherlands
        Roderick van den Bergh
      Sep 10, 2022

      Prostate Cancer, Prostate Adenocarcinoma Trial in Charlotte (ADT+Docetaxel+Enzalutamide)

      Active, not recruiting
      • Prostate Cancer
      • Prostate Adenocarcinoma
      • Charlotte, North Carolina
        Levine Cancer Institute
      Jan 12, 2023

      Prostate Cancer Metastatic, Radiation Therapy, Positron-Emission Tomography Trial in Umeå, Jönköping (stereotactic body

      Recruiting
      • Prostate Cancer Metastatic
      • +2 more
      • stereotactic body radiotherapy
      • +2 more
      • Umeå, Umea, Sweden
      • +1 more
      May 19, 2022

      Prostate Adenocarcinoma, Prostate Cancer, Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Trial in Boston (Apalutamide

      Not yet recruiting
      • Prostate Adenocarcinoma
      • +2 more
      • Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi]
      • Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan
      • Boston, Massachusetts
        Beth Israel Deaconess Medical Center
      Jan 4, 2023

      Prostate Cancer Metastatic Trial in New York (REGN2810, Degarelix, Leuprolide Acetate)

      Recruiting
      • Prostate Cancer Metastatic
      • New York, New York
        Columbia University Irving Medical Center
      Mar 22, 2022

      Metastatic Hormone Sensitive Prostate Cancer Trial in China (Enzalutamide, Placebo, Androgen deprivation therapy (ADT))

      Active, not recruiting
      • Metastatic Hormone Sensitive Prostate Cancer
      • Beijing, China
      • +29 more
      Jan 7, 2023

      Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Trial in Nanjing (6-month course of antiandrogen drugs, Long-term course of

      Recruiting
      • Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
      • 6-month course of antiandrogen drugs
      • Long-term course of antiandrogen drugs
      • Nanjing, Jiangsu, China
        Urology dpt, First Affiliated Hospital of Nanjing Medical Univer
      Jul 13, 2023

      Metastatic Prostate Cancer Trial in Spain (Enzalutamide, Talazoparib)

      Recruiting
      • Metastatic Prostate Cancer
      • Badalona, Spain
      • +8 more
      Jan 18, 2023

      Prostate Cancer, Prostate Cancer Recurrent, Prostate Cancer Metastatic Trial in Leuven (Radiotherapy (SBRT) and/or surgery

      Recruiting
      • Prostate Cancer
      • +6 more
      • Radiotherapy (SBRT) and/or surgery (metastasectomy)
      • +2 more
      • Leuven, Belgium
        University Hospitals Leuven
      Jun 7, 2022

      Prostate Cancer Trial in Salt Lake City (Rucaparib)

      Active, not recruiting
      • Prostate Cancer
      • Salt Lake City, Utah
        Huntsman Cancer Institute
      Jun 23, 2022

      Metastatic Prostate Cancer, Castration-Sensitive Prostate Cancer Trial in Shanghai (drug, procedure, radiation)

      Not yet recruiting
      • Metastatic Prostate Cancer
      • Castration-Sensitive Prostate Cancer
      • Shanghai, Shanghai, China
      • +1 more
      Feb 4, 2023